Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation.

Autor:	Cao JH; Department of Ophthalmology, School of Medicine, University of Colorado, Aurora, Colorado., Mulvahill M; Colorado Biostatistics Consortium, School of Public Health, University of Colorado, Aurora, Colorado., Zhang L; Colorado Biostatistics Consortium, School of Public Health, University of Colorado, Aurora, Colorado., Joondeph BC; Colorado Retina Associates, P.C., Denver, Colorado., Dacey MS; Department of Ophthalmology, School of Medicine, University of Colorado, Aurora, Colorado; Colorado Retina Associates, P.C., Denver, Colorado. Electronic address: mdacey@retinacolorado.com.
Jazyk:	angličtina
Zdroj:	Ophthalmology [Ophthalmology] 2014 Oct; Vol. 121 (10), pp. 1871-6. Date of Electronic Publication: 2014 Jun 03.
DOI:	10.1016/j.ophtha.2014.04.012
Abstrakt:	Purpose: To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis. Design: Retrospective chart review. Participants: A total of 27 consecutive patients with persistent macular edema resistant to standard short-term therapy despite quiescent noninfectious intermediate or posterior uveitis. Methods: Each patient was treated with a DEX 0.7 mg implant. Main Outcome Measures: Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection. Results: A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation. Conclusions: The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events. (Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu